SAINT-CLOUD, France, September 17, 2018 /PRNewswire/ --
Ethypharm's Supervisory Board is delighted to announce the appointment of Bertrand Deluard as Group CEO. This appointment takes effect on 1 October 2018.
Current President and CEO Hugues Lecat will remain the Group's Executive President until the summer of 2019, and will then take over from Gilles Brisson as President of the Supervisory Board. We will still benefit from Gilles Brisson's experience as he will remain a member of the Board.
Bertrand Deluard, who is 57, has more than 30 years' experience within the drugs and medical devices industry, having worked for the biggest groups, both French (Rhône Poulenc, Aventis et Sanofi) and international (GSK, Johnson & Johnson, Cardinal Health). He thus has a strong background in general management within the various types of market in France and abroad. He was, until now, the Europe, Middle East and Africa President of the American company Cardinal Health, which he has expanded considerably over the past three years by means of organic growth and campaigns to boost external growth.
In the words of Hugues Lecat, "Bertrand was a natural choice for us to take the helm of the Group. His leadership, willingness to listen and ability to manoeuvre within complex environments are undeniable assets for Ethypharm's ongoing transformation and growth."
Bertrand Deluard himself says, "I feel immensely proud to be joining Ethypharm, and intend to accelerate the Group's growth and internationalisation. A central part of this project is the focus on specific therapeutic domains in order to keep improving our response to the expectations and needs of patients and healthcare professionals."
Ethypharm is a European-based specialty pharmaceutical company with global reach and a committed player in the treatment of pain and addiction.
Ethypharm also develops and markets complex generics and essential medicines that help reduce healthcare costs, particularly in the field of emergency care and oncology.
The Company employs 1400 people mainly in Europe, and its drugs are marketed in more than 80 countries.
Our ambition is to become the European leader for the treatment of pain and addiction, and to help patients around the world gain access to high quality, essential and affordable medicines.
To learn more about the Ethypharm Group, visit our website: http://www.ethypharm.com
SOURCE Ethypharm Group